SIGFOX
28.2.2020 12:18:09 CET | Business Wire | Press release
An Post, the leading mails, parcels and ecommerce logistics company in Ireland, has contracted VT-IoT, the operator of Ireland’s Sigfox 0G network to revolutionise their supply chain with IoT tracking devices as part of their innovative and fast-moving digital transformation strategy.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200228005183/en/
As masters of delivery, An Post Mails & Parcels is rapidly changing from the old world of traditional letters to the new world of ecommerce parcel logistics and B2B services for Irish and international businesses. An Post runs Ireland’s largest fleet, including the country’s largest fleet of electric vehicles. It recently opened its new fully automated Dublin Parcel Hub and its operational infrastructure includes a large volume of returnable transport units such as roll cages and containers.
To provide an efficient and cost-effective service, An Post require a systematically integrated operational process. The roll cages and containers in which parcels are transported must be available every day in the required quantities in the Company’s mails hubs across the country.
With the advance of revolutionary Internet of Things (IoT) technology, VT and Sigfox are providing An Post with the solution they need to optimise their supply chain. Smart tracking devices empower An Post to monitor the location of their assets nationwide, even outside their own supply chain. Using Sigfox, the world’s leading IoT service provider and first global 0G network operator, has eliminated the barriers associated with traditional tracking technologies: price, battery life and coverage, by providing low cost, low power connectivity over a single global network today available in more than 70 countries.
“VT’s state-of-the-art solution has resulted in significantly increased transparency in our postal distribution network, ensuring world class quality of service for our customers and lower operational costs through improved containerisation efficiency”, explains Mark Devine, National Engineering Maintenance & Performance Manager, An Post .
“Our collaboration with An Post is an exciting step forward into the future of industrial IoT and a key milestone toward connecting billions of IoT devices globally on the Sigfox 0G network. We are confident our solutions have the power to truly revolutionise the way logistics and supply chain companies do business, resulting in significantly reduced costs and increased efficiencies .” Mark Bannon, CEO, VT.
““We are delighted to support An Post in this new era of industry 4.0, where we are making the once untraceable now entirely visible to organisations. We continue to deliver benefits to Postal organisations, like An Post in Ireland, DHL in Germany and Posti in Finland. This is a key vertical for Sigfox, where we strive to deliver value and thought leadership in Global Supply Chain & Logistics." Glen Robinson, SVP Global Sales & Marketing, Sigfox.
About An Post
An Post provides world-class mails, e-commerce parcels, financial and communications services to national and international business. It delivers two million items of mail to 2.2 million address points nationwide every working day, as well as evening and weekend parcels deliveries.
About VT
VT is a 0G IoT network operator and a pioneer of IoT solutions within the Supply Chain and Aerospace markets. Our purpose is to empower our enterprise users to transform their business models and operations through our leading-edge device to cloud 0G solutions. Our nationwide Sigfox IoT telecoms network currently delivers over 95% geographical coverage to Ireland – we are passionate about enabling every person, home and business to benefit from 0G IoT.
About Sigfox
Sigfox is the initiator of the 0G network and the world’s leading IoT (Internet of Things) service provider. Its global network allows billions of devices to connect to the Internet, in a straightforward way, while consuming as little energy as possible. Sigfox’s unique approach to device-to-cloud communications addresses the three greatest barriers to global IoT adoption: cost, energy consumption and global scalability.
Today, the network is available in 70 countries, with 1 billion people covered. ISO 9001 certified and surrounded by a large ecosystem of partners and IoT key players, Sigfox empowers companies to move their business model towards more digital services, in key areas such as Asset Tracking and Supply Chain. Founded in 2010 by Ludovic Le Moan and Christophe Fourtet, the company is headquartered in France and has offices in Madrid, Munich, Boston, Dallas, San Jose, Dubai, Singapore, Sao Paulo and Tokyo.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200228005183/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NTT DOCOMO BUSINESS and Chile’s State-owned Copper Company CODELCO Launch a Study and Proof of Concept Aimed at Improving the Efficiency of Remote Copper Mine Operations Using IOWN® APN6.8.2026 06:30:00 CEST | Press release
NTT DOCOMO BUSINESS, Inc. (formerly NTT Communications Corporation) has launched a study and proof of concept jointly with Corporación Nacional del Cobre de Chile (CODELCO) to progress remote operations at CODELCO’s copper mines using an IOWN® All-Photonics Network (APN).1 This initiative is part of a research project commissioned by Japan’s Ministry of Internal Affairs and Communications.2 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260806845222/en/ Conceptual Diagram of the Demonstration To address operational challenges faced by CODELCO’s copper mines, the initiative will connect a copper mine and a remote operations center—approximately 1,500 km apart—via an IOWN APN. It will assess the feasibility of remotely operating heavy machinery using high-capacity, low-latency communication links, enhancing monitoring operations through high-definition video, and implementing a remote operations model. 1. Background Chile is o
FPT Named an OpenAI Select Partner6.8.2026 02:00:00 CEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 00:10:00 CEST | Press release
Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of OR
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 22:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 16:05:00 CEST | Press release
Bob Dagher, M.D., Named Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., Named Principal Investigator Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
